Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CircFam53B-219aa DC Vaccine in HER2-negative Advanced Breast Cancer
NCT06530082Phase 1Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2024
- Primary completion
- Apr 2026
- Modality
- Peptides
01
Overview
Phase 1, open-label trial of CircFam53B-219aa in breast cancer (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicity at 21 days and Incidence of Grade >=3 Treatment-Emergent Adverse Event at 21 days. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
CircFam53B-219aa
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06530082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06530082.